论文信息 - Is also the patient ready for switching from intravenous to subcutaneous biologicals? - 字舞流文

Is also the patient ready for switching from intravenous to subcutaneous biologicals?

P. Bossuyt | L. Pouillon | K. Asnong

[1] S. Vermeire,et al. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn’s Disease: Results From the VISIBLE 2 Randomised Trial , 2021, Journal of Crohn's & colitis.

[2] Sang Joon Lee,et al. Randomized Controlled Trial: Subcutaneous versus Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. , 2021, Gastroenterology.

[3] S. Bonovas,et al. Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. , 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[4] Marien González-Lorenzo,et al. Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar‐treated IBD patients , 2019, Alimentary pharmacology & therapeutics.